Disc Medicine IRON Proceeds From Sale Of Common Stock In Underwritten Offering Net Of Issuance Costs Paid
Proceeds From Sale Of Common Stock In Underwritten Offering Net Of Issuance Costs Paid at other companies
Other financials
Where this comes from
Reported directly by Disc Medicine in its filing.
Tagged under the XBRL concept iron:ProceedsFromSaleOfCommonStockInUnderwrittenOfferingNetOfIssuanceCostsPaid.
The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Disc Medicine's proceeds from sale of common stock in underwritten offering net of issuance costs paid.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Disc Medicine's proceeds from sale of common stock in underwritten offering net of issuance costs paid?
- Disc Medicine (IRON) reported proceeds from sale of common stock in underwritten offering net of issuance costs paid of $0 in Q1 2026.
- How has Disc Medicine's proceeds from sale of common stock in underwritten offering net of issuance costs paid changed year-over-year?
- Disc Medicine's proceeds from sale of common stock in underwritten offering net of issuance costs paid decreased by 100.0% year-over-year, from $234M to $0.
- What does proceeds from sale of common stock in underwritten offering net of issuance costs paid mean?
- This represents the net cash proceeds received from the issuance of common stock through underwritten public offerings, after deducting issuance costs. It serves as a primary indicator of the company's ability to raise significant capital from equity markets to fund operations or growth. High proceeds indicate strong investor demand and successful capital market access.